Never freeze a reconstituted vial, as that can ruin it
What to Expect in Months 7-11 Essentially no side effects: Appetite suppression continues (desired effect), but GI symptoms gone Weight loss velocity slows: From 0.8kg/week (months 3-6) to 0.3-0.5kg/week Plateau around week 40-48: Weight stabilizes, no longer losing despite continued medication Total weight loss: Average 20-24% from baseline (matching or exceeding surgical outcomes) Focus shifts to maintenance: Accepting current weight, preventing regain Plateau frustration: Not a side effect but an emotional challenge 2 Final Strategies for Months 7-11 20
Results The study consisted of 150 patients, with 73 GLP-1 RA users in the experimental group and 77 non-users in the control group
Melatonin levels urinary 6-sulfatoxymelatonin (overnight collection) is the standard research measure Cortisol rhythm morning and evening salivary cortisol to assess circadian regulation Inflammatory markers hsCRP, IL-6 as general aging biomarkers Fasting glucose and insulin epithalamin showed effects on glucose metabolism in aged primates (Khavinson et al., 2005) Subjective Tracking Energy journal daily 1-10 rating at consistent times Skin quality photos same lighting, same angle, monthly Recovery from exercise or minor illness note any changes in bounce-back time Mood and cognitive clarity brief daily notes Best Practices Documented tracking approaches establish all baselines before the first Epitalon cycle, with biomarkers tested at least 2 weeks before starting
Studies suggest Ipamorelin and GHRP-2 may increase GH more in women but lead to different fat loss and muscle-building effects
After adding BCH and incubating with LAAM GSH-CQDs, both the expression level of LAT1 on the cell membrane and in the cell cytoplasm did not show significant changes at various incubation times (Supplementary Fig